Deferasirox
Iron Overload
Kevin H.M. Kuo, MD, MSc, FRCPCSmall moleculePhase 4 / ApprovedDormant
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Iron Overload cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DESFERRIOXAMINE B Beni-Suef University | Phase 4 | BBB |
Deferiprone Chiesi Canada Corp | Phase 4 | BBB |
AMLODIPINE Kevin H.M. Kuo, MD, MSc, FRCPC | Phase 3 | BB |
Hydroxyurea Beni-Suef University | Phase 2/3 | B |
Nigella Sativa Oil Beni-Suef University | Phase 2/3 | B |
View all 11 →
Same molecule, other indications
Deferasirox is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →